Zacks8d agobullish
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
530last 24h
2506last 7d
477● bullish (7d)
255● bearish (7d)
197publishers
Quartz8d agobearish
Johnson & Johnson settling talc baby powder lawsuits for $5.5 billionThe deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect
Associated Press8d agoneutral
Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fightJohnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least 95% of remaining claimants participating. A U.S. bankruptcy court judge denied a $9 billion settlement proposed by company subsidiary Red River Talc last year that would have been one of the biggest mass tort settlements in history.
The Telegraph8d agoneutral
Johnson & Johnson offers £4.1bn to settle talcum powder cancer claimsJohnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.
The Telegraph8d agoneutral
Johnson & Johnson offers £4.1bn to settle talcum powder cancer claimsJohnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.
Reuters Videos8d agoneutralVIDEO
Johnson & Johnson reaches $5.5 billion baby powder settlement<body><p>STORY: :: New York / July 27, 2026</p><p>:: Dietrich Knauth, Legal Reporter</p><p>"After years of litigation, about 70,000 court cases, and three bankruptcies, Johnson& Johnson has agreed to a $5.5 billion talc settlement. Why are they settling now? </p><p>:: Why did J&J settle after more than a decade of talc litigation?</p><p>"So tens of thousands of women have accused Johnson& Johnson of causing their ovarian cancer. They've alleged that talc-based products, including baby powder, have been contaminated with asbestos and caused them to develop cancer after using these products for a long period of time. Johnson& Johnson has denied that, but these cases have continued to go to trial."</p><p>"And after a couple of attempts to settle these cases through bankruptcy courts, Johnson& Johnson has now reached a deal where they think they can end all of these cases for an overall payment that is about $5.5 billion, although that number could rise depending on how many people participate in the settlement."</p><p>"One of the plaintiff's lawyers told me today that he thinks it's closer to $7 billion. That's not something we're going to know for some time."</p><p>:: Could J&J still face new talc lawsuits in the future?</p><p>:: Johnson & Johnson</p><p>"It does not fully close the door on all future talc litigations. Somebody could develop cancer in the future, decide that they want to file a lawsuit against Johnson& Johnson, because they think that company's product caused their cancer. The reason for that is that there's something called a latency period, which is essentially the delay between when you experience the factors that caused your cancer and when that cancer actually shows up."</p><p>"But, you know, this deal basically gets rid of all of the existing cases. That's the idea."</p><p>J&J reached the settlement after a series of wins in court, including victories in individual trials, successful efforts to disqualify plaintiffs' lawyers from the litigation, and court rulings against experts that plaintiffs had used to prove their cases in court. </p><p>J&J won a significant court victory in the long-running legal battle last week, when a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer.</p><p>J&J has long denied that its talc products caused cancer, saying that talc was safe and did not contain asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.</p><p>Before the bankruptcy attempts, J&J had a mixed record in talc trials, with a multibillion verdict in favor of 22 women who said baby powder caused their ovarian cancer. The company won some trials outright and had other verdicts reduced on appeal.</p><p>Unlike the proposed bankruptcy settlements, Monday's agreement applies only to existing claims and does not address future lawsuits.</p></body>
The Wall Street Journal8d agoneutral
Stocks to Watch: SK Hynix, Mercedes-Benz, Boeing, Coca-Cola↘️ Samsung (KR:005930), SK Hynix (KR:000660, SKHY): Shares in both chipmakers dropped more than 13% as part of a broader selloff amid mounting doubts over the AI boom. Over in the U.S., Micron Technology (MU), Intel (INTC) and other chip stocks are also sliding premarket.
MT Newswires8d agoneutral
Johnson & Johnson Proposes to Pay Up to $5.5 Billion to Resolve Remaining Ovarian Cancer ClaimsJohnson & Johnson (JNJ) has agreed to commit up to $5.5 billion to settle about 76,000 lawsuits that
Zacks8d agoneutral
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios PharmaceuticalsHRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.
CBS News8d agobearish
Johnson & Johnson offers $5.5 billion to settle talc lawsuitsJohnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.
Sky News8d agobearish
J&J offers $5.5bn to settle baby powder lawsuitsJohnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma. J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as "meritless".
24/7 Wall St.8d agoneutral
Why Chasing a 9% Yield Could Cost You $200,000 in Retirement IncomeThe yield you chase in retirement does not just shape your income, it determines whether your portfolio outlasts you or quietly devours itself. Two investors with the same $600,000 can end up hundreds of thousands of dollars apart depending on one number.
The Wall Street Journal8d agobearish
Johnson & Johnson Agrees to Pay Up to $5.5 Billion to Settle Talc LawsuitsThe company said it reached an agreement with firms representing plaintiffs in the outstanding talc cases to pay up to $3 billion in claim payments in 2027, with no further payments due before 2028.
Stocktwits8d agoneutral
JNJ Stock Advances After Hours On $5.5B Proposal To Resolve Talc LitigationThe healthcare company said the agreement covers the remaining ovarian talc litigation in federal multidistrict litigation proceedings and related state court cases.
Reuters8d agoneutral
Johnson & Johnson announces $5.5 billion settlement of talc lawsuitsBy Dietrich Knauth NEW YORK, July 27 (Reuters) - Johnson & Johnson said on Monday it has reached a $5.5 billion settlement that will resolve tens of thousands of lawsuits alleging its baby powder and
Insider Monkey8d agoneutral
Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]
The Wall Street Journal9d agobearish
🔎 Under the Radar: Legend Stock Tumbles After CEO DepartsShares of Legend Biotech fell 14% Monday after the company announced that CEO Ying Huang stepped down and left the board. Legend said in a regulatory filing that Huang’s resignation was not the result of a disagreement with the company, but didn’t say anything more about why he left. Huang said he was departing the company to work with a venture fund focusing on drug development.
Zacks9d agoneutral
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Zacks9d agoneutral
J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.
24/7 Wall St.9d agoneutral
Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a PaycheckA 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.
Insider Monkey9d agobearish
President Trump Loves Johnson & Johnson (JNJ), But Insiders Are SellingJohnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]
Zacks9d agoneutral
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & JohnsonGM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.
24/7 Wall St.9d agoneutral
A $550,000 Portfolio That Quietly Pays a 62-Year-Old $3,400 a Month Until Social Security Kicks InStopping work at 62 while waiting for a bigger Social Security check sounds clean on paper, but the math gets complicated fast when a portfolio has to carry the entire household for years. Here is how much capital different yield strategies actually require, and which tradeoffs could quietly wreck the plan.
24/7 Wall St.10d agobearish
How to Build $4,000 a Month in Dividend Income Without Selling a Single ShareGenerating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.
Motley Fool10d agobullish
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?Both have very promising futures.